Session date: 
Wednesday, March 23, 2016 - 11:00am to 12:00pm
Location: 
ISTH Webinar Library Once a Month
Carrboro, NC 27510
United States
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.
Program Description: 

Through its educational arm, the ISTH Academy, the International Society on Thrombosis and Haemostasis (ISTH) has begun hosting a series of webinars on practical thrombosis and haemostasis issues that scientists and physicians frequently confront. These webinars will allot time for participants to ask questions and will cover the latest information on relevant topics.

Speakers:
Peter Collins - "Clinical trials of enhanced half-life FVIII and FIX"
Gary Gilbert - "Experimental therapies"
Moderator:  David Lillicrap
 
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
 
Designation of Credit Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
More information and online registration:  http://www.prolibraries.com/isth/
 

This meeting is being supported by Instrumentation Laboratory


 
Target audience: 

Trainees and fellows interested in learning about the new and upcoming treatments for hemophilia

Learning objectives: 

At the conclusion of this activity, I will be able to:

  • Understand the rationale for experimental therapies and the untested assumptions that are likely to influence the degree of success.
  • Gain knowledge of the preclinical rationale and the early clinical data for experimental therapies that are in trials.
Faculty & credentials: 
Planning Committee:
Geoffrey Barnes, MD
Chris Ward, PhD
Stephen Watson, PhD
 
Speakers:

Peter Collins - "Clinical trials of enhanced half-life FVIII and FIX"

Gary Gilbert - "Experimental therapies"

 
Moderator:
David Lillicrap
 
 
 
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:  
 

Name

Company

Role

Geoffrey Barnes, MDPortolaConsulting
 Blue Cross Blue Shield of MichiganResearch
 BMS/PfizerResearch
Chris Ward, PhDBayerSpeaker
 Boehringer-IngelheimSpeaker, Advisory Board
 BMS/PfizerSpeaker, Advisory Board
Gary GilbertBaxaltaAdvisory Board
 BayerAdvisory Board
 Harvard Med School/VA HealthcareInventor
Peter CollinsNovo NordiskConsultant
 SobiConsultant
 BaxaltaConsultant

In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved

CME Coordinator Contact Information

Name: 
Lacey Schmeidler, MA
Phone number: 
+1 (919) 929-3807